Patents by Inventor Helmut Heinrich Buschmann

Helmut Heinrich Buschmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
    Patent number: 11739049
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: August 29, 2023
    Assignee: Grünenthal GmbH
    Inventors: Wolfgang Hell, Oswald Zimmer, Helmut Heinrich Buschmann, Joerg Holenz, Stefan Gladow
  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 11419873
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: August 23, 2022
    Assignee: WEX MEDICAL LIMITED
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20210252004
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 19, 2021
    Applicant: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
    Publication number: 20210130282
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 6, 2021
    Applicant: GRÜNENTHAL GMBH
    Inventors: WOLFGANG HELL, OSWALD ZIMMER, HELMUT HEINRICH BUSCHMANN, JOERG HOLENZ, STEFAN GLADOW
  • PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
    Publication number: 20200299225
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Applicant: GRUNENTHAL GMBH
    Inventors: WOLFGANG HELL, OSWALD ZIMMER, HELMUT HEINRICH BUSCHMANN, JOERG HOLENZ, STEFAN GLADOW
  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 10624896
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 21, 2020
    Assignee: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
    Publication number: 20190263747
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: WOLFGANG HELL, OSWALD ZIMMER, HELMUT HEINRICH BUSCHMANN, JÖRG HOLENZ, STEFAN GLADOW
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20190160074
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Applicant: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF
    Publication number: 20190010128
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Application
    Filed: February 1, 2018
    Publication date: January 10, 2019
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 10149852
    Abstract: The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogs/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: December 11, 2018
    Assignee: WEX PHARMACEUTICALS INC.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens, Susan Lu, Donald Wong, Walter Korz
  • 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
    Patent number: 9914705
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: March 13, 2018
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
    Patent number: 9850198
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: December 26, 2017
    Assignee: GRUENENTHAL GMBH
    Inventors: Helmut Heinrich Buschmann, Joerg Holenz
  • PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
    Publication number: 20170217875
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Wolfgang HELL, Oswald ZIMMER, Helmut Heinrich BUSCHMANN, Jörg HOLENZ, Stefan GLADOW
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20170000797
    Abstract: The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 5, 2017
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens, Susan Lu, Donald Wong, Walter Korz
  • Process for Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds
    Publication number: 20160257640
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: Helmut Heinrich BUSCHMANN, Joerg HOLENZ
  • PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
    Publication number: 20160221928
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: April 12, 2016
    Publication date: August 4, 2016
    Inventors: Wolfgang HELL, Oswald ZIMMER, Helmut Heinrich BUSCHMANN, Jörg HOLENZ, Stefan GLADOW
  • Sigma Ligands For the Prevention or Treatment of Pain Induced by Chemotherapy
    Publication number: 20160220575
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • Co-crystals of tramadol and NSAIDs
    Patent number: 9393220
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 19, 2016
    Assignee: LABORATORIES DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Lluis Sola Carandell, Jordi Benet Buchholz, Jordi Carles Ceron Bertran, Carlos Ramon Plata Salaman, Nicolas Tesson
  • Sigma Ligands For the Prevention or Treatment of Pain Induced by Chemotherapy
    Publication number: 20160199380
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 14, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
    Patent number: 9388119
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: July 12, 2016
    Assignee: GRUENENTHAL GMBH
    Inventors: Helmut Heinrich Buschmann, Joerg Holenz